Cargando…

Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy

We started a single-arm, phase II, open-label, prospective clinical trial using steroids-ruxolitinib as the first-line therapy for intermediate- to high-risk aGVHD (NCT04397367). Here, we report the association of a biomarker panel (sST2, REG3α, sTNFR1, IL-6 and IL-8) with responses to GVHD therapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jingjing, Peng, Bo, Wang, Lu, Li, Xin, Li, Fei, Jin, Xiangshu, Jia, Mingyu, Xu, Lingmin, Dou, Liping, Liu, Daihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610441/
https://www.ncbi.nlm.nih.gov/pubmed/34816294
http://dx.doi.org/10.1007/s00277-021-04727-1